Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3857)	2/20/1998 5:29:00 PM
From: Oliver & Co	Read Replies (2) \| Respond to of 6136

I received by fax today, from Priority Pharmacy (they send this to all HIV treaters), their "Priority News". It was about Nelfinavir used in BID Dosing and the positive results of the 1250 mg dose. It looks like they are endorsing the use of the BID dose. Positive for AGPH. I would expect usage to increase. Also note that TID dosing is 9 pills a day, BID is 10 pills a day. Agouron will have to increase the number of pills in the stock bottles by 30 (therefore an increase in price). BTW, it finally hit $40 today.